Key result
Circulating levels of miR-17 and miR-106a were significantly higher in BAV patients with less dilated versus severely dilated aortas and downregulated in those experiencing adverse aortic events.
Why the study?
Do circulating microRNAs correlate with the severity of aortopathy and adverse aortic events in patients with bicuspid aortic valve?
Observational (n=63)
Do circulating microRNAs correlate with the severity of aortopathy and adverse aortic events in patients with bicuspid aortic valve?
p-value: p=0.02
Circulating miR-17 and miR-106a correlate with the severity of aortopathy and risk of adverse aortic events in patients with bicuspid aortic valve, suggesting their potential as biomarkers.
May support miRNA biomarker development in BAV aortopathy; leaves open additive value to imaging before clinical adoption.
OBJECTIVES: We aimed to evaluate the impact of microRNAs to predict the bicuspid aortic valve (BAV)-associated aortopathy. METHODS: Sixty-three BAV patients (mean age 47 ± 11 years, 92% men) with root dilatation, who underwent aortic valve ± proximal aortic surgery (mean post-AVR follow-up 10.3 ± 6.9 years) were included. The BAV aortopathy entities were categorized in the 'less dilated' (aortic root <50 mm) and 'severely dilated' (aortic root ≥50 mm) aorta. Several microRNAs were assessed using polymerase chain reaction. End-points were the correlation between microRNAs and severity of aortopathy/prevalence of adverse aortic events. RESULTS: Circulating levels of miR-17 and miR-106a were strongly correlated (r = 0.84, P < 0.001). Our analysis yielded significantly higher values of miR-17 (delta Ct 2.09 ± 0.64 vs delta Ct 1.68 ± 0.64, P = 0.02) and miR-106a (delta Ct 5.88 ± 0.43 vs delta Ct 5.61 ± 0.60, P = 0.046) in BAV patients with the less dilated versus the severely dilated aorta. miR-17 (delta Ct 1.51 ± 0.73 vs delta Ct 2.00 ± 0.61, P = 0.02) and miR-106a (delta Ct 5.39 ± 0.69 vs delta Ct 5.85 ± 0.44, P = 0.007) were significantly downregulated in BAV patients who experienced adverse aortic events. CONCLUSIONS: Expression of circulating miR-17 and miR-106a in the BAV root phenotype patients correlates with the severity of aortopathy and the risk of adverse aortic events. MicroRNAs have the potential to serve as biomarkers in the BAV-associated aortopathy.
No takes yet. Share an insight, caveat, or question.
Girdauskas et al. (2018) conducted an observational in Bicuspid aortic valve (BAV)-associated aortopathy (n=63). Circulating microRNAs (miR-17 and miR-106a) vs. Severely dilated aorta (≥50 mm) / absence of adverse aortic events was evaluated on Correlation between microRNAs and severity of aortopathy/prevalence of adverse aortic events (p=0.02). Circulating levels of miR-17 and miR-106a were significantly higher in BAV patients with less dilated versus severely dilated aortas and downregulated in those experiencing adverse aortic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: